Background: Injectable naltrexone for alcohol use disorders (AUDs) has been efficacious in several studies. It has not been (i) compared head-to-head with oral naltrexone or (ii) examined in the hospital setting as an intervention that might facilitate treatment attendance after hospital discharge.
A LCOHOL USE DISORDER (AUD) is a highly prevalent and crucial health issue in the United States. In 2013, 14.7 million people met criteria for alcohol dependence or abuse, but only 10% received needed treatment (Substance Abuse and Mental Health Services Administration, 2014). Rates of AUDs among veterans (particularly among combat-exposed veterans) exceeded those in the general population, and fewer than 4% of veterans receiving care in the Department of Veterans Healthcare System with high alcohol consumption initiate specialized addiction treatments (Glass et al., 2010) . Factors more common among veterans, such as traumatic brain injury and posttraumatic stress disorder, may interfere with their participation in treatment (Bernhardt, 2009) . Further, alcohol and other substance-use disorders have been found to be the most stigmatized of the psychiatric conditions, and stigma has been associated with poorer adherence to pharmacological treatment (DiIorio et al., 2003; Livingston and Boyd, 2010) .
High levels of alcohol consumption and AUD cause myriad disorders involving the cardiovascular, gastrointestinal (GI), hepatic, neurologic, renal, and endocrine systems (Rehm et al., 2010; Ries et al., 2014) . Patients with AUDs, including veterans, are therefore more frequently hospitalized than the general population. The prevalence of AUDs among hospitalized patients has been estimated to be 4 to 5 times that of the general adult, nonhospitalized population (Bostwick and Seaman, 2004; Roche et al., 2006) .
Even when an AUD precipitates or complicates a hospitalization, recommended treatment is rarely accessed postdischarge. While brief advice to cut down on alcohol use has been successful in facilitating behavior change in outpatient settings, such strategies have been ineffective in the inpatient setting, likely due to the increased severity of AUDs among hospital inpatients versus the general population (Saitz, 2010; Saitz et al., 2007) . The transition from hospital or other institutional settings to community is a critical phase for individuals with AUDs, and methods to foster treatment initiation before discharge and engagement after discharge are needed. In VA healthcare facilities in 2013, rates of follow-up addiction treatment within 60 days of receiving detoxification for alcohol or opioids in inpatient or outpatient settings were 50% nationally (range 13 to 77%) (Timko et al., 2016) .
Pharmacotherapy to curb alcohol use is one intervention, which might be initiated prior to a hospital discharge to facilitate reduction in alcohol consumption and, subsequently, improve treatment engagement. The Food and Drug Administration-approved pharmacotherapy naltrexone is available in 2 forms (oral and injectable formulations) to reduce craving for alcohol and assist patients in their recovery from AUDs. Nonadherence to daily at-home dosing has been a barrier to sustained recovery when oral preparations are used (Krystal et al., 2001; Pettinati et al., 2006; Volpicelli et al., 1997) . Long-acting, monthly injectable naltrexone may overcome the challenge of adhering to a daily oral medication. If medication adherence is major barrier to reducing alcohol use after hospital discharge, reducing long-acting naltrexone injection prior to discharge from a controlled environment (i.e., hospital or residential facility) might more effectively reduce alcohol use after discharge, and facilitate meaningful participation in behavioral treatment. Injectable naltrexone in addition to behavioral treatment has been efficacious in several studies (Ciraulo et al., 2008; Comer et al., 2006; Garbutt et al., 2005) . However, it has yet to be examined (i) in head-to-head comparison with daily oral naltrexone or (ii) in the inpatient hospital setting as an intervention that might facilitate behavioral treatment attendance after hospital discharge. To begin to address this knowledge gap, this study sought to pilot methodology that could evaluate the effectiveness of oral naltrexone (taken orally once daily at home) versus long-acting injectable naltrexone (30-day duration of action) initiated prior to discharge from an inpatient hospitalization.
As a pilot proof-of-concept study, the work primarily sought to determine the feasibility of subject recruitment and of protocol completion by a substantial majority (>70%) of enrolled participants. Protocol completion was defined as participants completing all 3 data collection visits: baseline, day 14, and day 45. We also sought to calculate variance estimates to use in sample size estimation for future clinical study. 
MATERIALS AND METHODS

The
Study Design and Participants
Veterans hospitalized for an acute medical or psychiatric (i.e., not necessarily for purposes of medically managed detoxification) illness at the William S. Middleton Memorial Hospital and for whom alcohol withdrawal symptom monitoring was ordered by the admitting physician were recruited. To identify potentially eligible hospitalized veterans, study team members with appropriate clinical privileges and access (RB and ACB) received electronic notifications via the VA electronic health record (EHR) when symptom monitoring for alcohol withdrawal was ordered at the time of hospital admission. This identification was followed by a chart review to screen patients for basic eligibility criteria. A study coordinator approached patients who were at least 18 years old who had a clinically established diagnosis of alcohol dependence based on the DSM-IV-TR (American Psychiatric Association, 2000). The diagnosis was established based on clinical interview by an addiction counselor or addiction medicine physician, a process that is standard policy for any veteran for whom alcohol withdrawal monitoring is ordered at the study hospital and is an interaction documented in the EHR. Individuals were excluded if they had past-year opioid dependence, daily use of opioid analgesics, acute hepatitis or liver failure, suicidality, or if they were unable to provide written informed consent. Women were excluded if they were pregnant or currently breastfeeding. Before randomization, patients received a brief questionnaire, a liver function test, and a urine pregnancy test to verify eligibility. Pregnancy tests were repeated 1 month into the study. Baseline measurements were collected in the hospital prior to discharge. Telephone follow-up interviews occurred 14 and 45 days postdischarge. Medical records review was undertaken to ascertain attendance to treatment visits over the 90 days subsequent to the index hospitalization. Participants were compensated $50 for completing the baseline interview and $50 for the day 45 interview for a maximum total compensation of $100 per participant. Study procedures were recorded in an electronic subject tracking database maintained in REDCap, a secure, web-based application designed for research (Harris et al., 2009 ).
Interventions
The study coordinator, in the process of informed consent and enrollment, discussed the potential risks and benefits of naltrexone. Pertinent material to that end was included in the IRB-approved study consent document to be reviewed with potential participants. This risk-benefit material was guided by package inserts and the Micromedex Drug Reference (http://www.micromedexsolutions. com/micromedex2/librarian/pfdefaultactionid/evidencexpert.dointe gratedsearch#). Eligible and consenting veterans were randomized 1:1 to receive either: (i) a 50 mg oral naltrexone plus a 30-day prescription or (ii) a 380 mg intramuscular naltrexone injection prior to discharge. Participants randomized to the injectable naltrexone group were administered a single 380 mg intramuscular injection of naltrexone prior to discharge, which had a 30-day duration of action. Participants were scheduled for a return physician clinic visit 1 month later to receive a second injection. Those residing outside of the hospital's metropolitan area who received their primary care at a community-based VA clinic had the option to receive their second injection at that clinic. Individuals randomized to the oral naltrexone group received an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone, as well as a 15-day refill to be used after day 30. Refills in the oral condition could be received by mail or picked up in person at their preferred VA pharmacy.
Standard hospital-based care for all hospitalized veterans monitored for withdrawal included assessment and motivational enhancement by an addiction counselor to encourage engagement in addiction treatment. National VA performance measures monitor outpatient addiction treatment follow-up within 2 weeks of discharge for all patients diagnosed with AUD.
Randomization
The 1:1 randomization sequence was computer-generated. Sequentially numbered opaque envelopes were used to conceal randomization, which were opened by the interviewer following consent and the baseline interview. The randomization slip and consent form were immediately delivered to the pharmacy, which entered an order for the appropriate medication into the EHR for the Principal Investigator to sign.
Outcomes and Measurements
As a pilot study, the primary goal was to demonstrate a feasible study design. We recorded sufficient information to estimate rates of recruitment, randomization, intervention delivery, medication adherence, adverse events, and interview completion. We calculated enrollment per month (we sought to enroll approximately 6 participants per month in order to complete the study within 12 months) and rate of protocol completion. Protocol completion was defined as receiving the appropriate study medication after randomization and participating in all 3 phases of data collection (baseline, day 14, and day 45). Because this was a pilot study, we did not continue to interview patients who did not receive a study medication. Thus, we calculated protocol completion in 2 ways: (i) among all patients who were randomized and (ii) among those who were randomized and received a study medication (and thus, were contacted by the study team to complete the day 14 and 45 interviews). We also sought to calculate variance estimates to use in sample size estimation for the proposed primary and secondary outcome measures of a future clinical trial.
To assess medication adherence, participants assigned to the oral medication group were asked to self-report the number of missed doses over the previous 14 days at each follow-up. Adherence was operationalized as taking ≥80% of daily oral naltrexone doses. In the injectable naltrexone condition, medication adherence was defined as receiving the second naltrexone injection. We asked veterans how the medication was affecting them using open-ended questions. We monitored and recorded adverse study events in a web-based application managed by the University of Wisconsin's Health Sciences IRB.
The primary outcome planned for the future clinical trial was the receipt of postdischarge addiction treatment from substance-use disorder specialists. For analytic purposes, treatment initiation was defined as attendance to at least 1 specialist treatment visit in the 2 weeks after hospital discharge. Treatment engagement was examined in 2 ways: at least 3 visits in the 30 days postdischarge and 2 or more visits per month in each of the 3 months following discharge. Treatment was ascertained via a chart review of medical records beginning on the date each individual participant was discharged from the inpatient hospital setting and ending 90 days thereafter. Note titles and visit locations were abstracted from the EHR and used to identify visits associated with treatment from substance-use disorder specialists. The research team, which included a staff physician and psychologist at the study site, consulted with a clinical applications coordinator to determine appropriate data elements for the chart review. The chart review captured visits occurring at any VA medical center or community-based VA clinic.
Secondary outcomes included postdischarge alcohol consumption and hospital readmissions. Alcohol consumption for the prior 14-day period was queried at each interview via the timeline followback method (Sobell and Sobell, 1992) . We calculated the presence of heavy drinking days (yes/no; >4 standard drinks on a day in the last 14), number of heavy drinking days (range 0 to 14), and the total number of drinks in the past 14 days. At baseline, veterans were asked to complete this interview in reference to the 14 days prior to their hospitalization. The chart review captured hospital admissions occurring at any VA hospital locations in psychiatric, general medical, surgical, or intensive care wards in the 90 days after the index hospitalization.
Sociodemographic characteristics were obtained using the Addiction Severity Index-Lite (Cacciola et al., 2007; McLellan et al., 1992) . To evaluate the feasibility of data collection for a future trial, in which comorbid mental health conditions would be used as statistical controls and potential moderating variables, we administered the Generalized Anxiety Disorder Screener (GAD-7) (L€ owe et al., 2008) to measure anxiety severity, the Patient Health Questionnaire (PHQ-9) (Manea et al., 2015) to measure depression, and the Mini International Neuropsychiatric Instrument (Sheehan et al., 1998) to assess for DSM-IV-TR posttraumatic stress disorder.
Sample Size Estimation
As above, we sought to obtain a sample of approximately 50 subjects based on available funding and time available for recruitment, expecting an accrual rate of approximately 6 subjects per month. Approximately 25 subjects per group would allow for the calculation of 95% confidence intervals (CIs) around the percentage of patients obtaining treatment in each group with an interval width of 40% if treatment utilization was 50% and down to an interval width of 27% if treatment utilization was 90%. In addition, 25 subjects per group would allow us to calculate 95% CIs around means of our secondary outcomes with accuracy of AE41.3% of the standard deviation (SD). For example, if the SD = 2, our 95% CI width would be AE0.826. As per published recommendations for pilot studies, we did not seek to obtain adequate statistical power to evaluate between-group differences in the study outcomes (Eldridge et al., 2016) .
Statistical Analyses
Subject characteristics, follow-up rates, medication adherence, and engagement rates were compared between treatment groups with t-test, Wilcoxon rank sum tests, and Fisher's exact tests. Total number of drinks and total number of heavy drinking days over time were summarized with median (range) at each time point.
Comparison of the change in outcome variables from baseline regardless of treatment group was made with paired t-tests. Analysis was based upon modified intention-to-treat principle, wherein veterans not receiving any intervention were not analyzed, because we did not proactively contact these patients for follow-up assessments (Cook and DeMets, 2008) . One veteran who was randomized to injectable naltrexone received oral and was analyzed as randomized.
RESULTS
Participant Flow
Recruitment and loss to follow-up are depicted in the CONSORT diagram in Fig. 1 . During the study period, there were a total of 385 EHR alerts of hospital admissions who were to be observed for the possible development of alcohol withdrawal symptoms. Of these, 74 veterans were not screened due to discharge prior to being approached or lack of available research staff, and 198 patients were excluded via chart review for applicable exclusions. One hundred and thirteen veterans were contacted and interviewed for eligibility. Exclusionary criteria included plan for discharge to a long-term controlled environment (e.g., skilled nursing facility), current opioid use or use disorder, psychosis, suicidal or homicidal ideation, medical contraindications, already on naltrexone, geographically distant residence, unable to complete consent, or if the patient did not meet alcohol dependence criteria. The most prevalent reasons for participant exclusions included 32% of patients having current medical contraindications (e.g., hepatitis, pancreatitis) and 29% of patients with current opioid use or physical dependence. A total of 59 eligible patients were excluded for the following reasons: 26 declined to participate, 20 were discharged prior to finishing consent, 11 were excluded due to plans to discharge to a controlled facility, and 2 did not meet criteria for alcohol dependence based upon baseline clinical interview by an addiction medicine physician or addiction counselor. Of the 54 participants enrolled in the study, 27 were randomized to the injectable naltrexone group and 27 were randomized to the oral naltrexone group. The specific hospital wards from which veterans were recruited are shown in Table 1 . Assignment to study arm did not significantly differ based upon hospital ward location. Of the veterans recruited, 13 (n = 7 in injection group and n = 6 in oral group) transitioned from the hospital to a brief (7 to 21 days) stay in a residential treatment unit. As this constituted a controlled environment, where risk for ongoing alcohol consumption would be negligible, medication administration occurred immediately prior to discharge from this environment, and follow-up measures were timed for 14 and 45 days after discharge from this environment. Twenty-one of 27 participants who were randomized to receive the injection received the intervention; 1 received oral and was analyzed as randomized (n = 22). Of the 27 randomized to the oral intervention group, 23 received an oral dose at baseline. Follow-up rates for the sample receiving medication (n = 45) were 82% at day 14 and 77% at day 45, with no significant difference in retention between study groups. Table 1 shows baseline characteristics for participants in each study group. Mean ages were 51 (SD = 15) and 48 (SD = 13) for oral and injection groups, respectively. Eightynine percent of the sample was Caucasian, 96% were male, 93% had at least completed high school, and 87% had an annual income of 50K or less. There were no significant differences between study groups in alcohol consumption, PHQ-9 scores, or GAD-7 scores. Baseline characteristics for the 9 veterans (5 in injection arm and 4 in oral arm) who consented but did not receive study medication were examined and found not to differ significantly by medication assignment, from the overall sample, or from participants who did not complete study follow-up.
Sample Characteristics
Outcomes and Estimation of Feasibility
Rates of protocol completion are as follows. Among those who were randomized (n = 54), 64.8% (n = 35) received a study medication and completed all follow-ups. Among those who received a study medication and were proactively followed (n = 45), 77% completed all follow-ups. The accrual time frame for recruitment (n = 54) was from September 5, 2013, to April 20, 2015, for a total accrual time of 19 months, and an overall accrual rate of 2.8 subjects per month on average. Barriers to achieving the goal of 6 participants per month overall included primarily the following: (i) a higher-than-expected rate of ongoing opioid use in the population, which was an exclusion criteria, and (ii) transitions in study team membership and need for IRB protocol revision, which led to a 3-month period (July to October 2014) during which we could not enroll patients. The rate of recruitment improved significantly when a researcher with privileges to screen using the EHR and who had a clinical role with the Alcohol and Drug Treatment Program (ACB) took over study eligibility determination, consent, and enrollment tasks; recruitment rate improved from 1.9 subjects to 4.4 subjects per month.
Postdischarge specialty addictions treatment engagement and retention are described in Table 2 . Rates of initial engagement (at least 1 visit within 14 days after hospital discharge) were high (86.4% for injection group, 78.3% for oral group) and did not differ significantly between treatment groups. The proportion receiving at least 3 visits in the first month was similar across groups (68.2% for injection group, 65.2% for oral group). The proportion retained in treatment over 3 months (2 visits per month) was 40.9% for injection group and 21.7% for oral group. This difference did not attain statistical significance. The absolute number of visits attended over 90 days also did not differ significantly by treatment group (p = 0.099).
The median number of drinks in the last 14 days (128) prior to hospitalization among the entire cohort was significantly higher than in day 14 (0, p < 0.001) and day 45 (0, p < 0.001). The median number of heavy drinking days in last 14 days prior to baseline among entire cohort (11) was significantly higher than in day 14 (0, p < 0.001) and day 45 (0, p < 0.001). There were no differences at any time point between treatment groups in either outcome (p > 0.05), and alcohol consumption descriptors did not differ between groups at any time point. Group comparisons on consumption at each time point are shown in Table 3 . Percentages of participants who had ≥1 hospital readmission by day 45 were similar between treatment groups (p > 0.05), and similar among medication adherent (62% of injection group and 61% of oral group met study definition of adherence, p > 0.05) versus nonadherent groups, indicating no 13 participants (6 in injection group and 7 in oral group) transitioned from hospital to a residential unit (7-to 21-day stay). Medication administration occurred at the time of discharge from the residential unit for these participants and 14-and 45-day follow-up assessments were timed based on discharge from the residential unit. significant differences in either outcome. Twenty-six percent of the total sample (n = 9) had ≥1 hospital readmission with 17% (n = 3) of participants readmitted within the medication adherent group and 43% (n = 6) nonadherent participants readmitted by day 45 (p > 0.05).
Effect sizes for treatment engagement and drinking outcomes were also calculated. The effect was considered small (Cohen's d 0.25; 95% CI for Cohen's d ranging from 0 to 0.80) and did not differ between treatment arms as expected for this small pilot trial. However, the data on both treatment engagement and drinking outcomes were highly right skewed (hence, the use of median as the preferred measure of central tendency for study outcomes), calling into question the precision of this estimate.
DISCUSSION
The results of the current work indicate potential feasibility for initiating a larger randomized clinical trial of alcohol pharmacotherapy for veterans with AUD during acute hospitalization. The recruitment rate did not reach the expected goal of 6 patients per month overall. This was primarily driven by high rates of regular opioid use in the target population and by transitions in research team roles. Future larger study would likely require (i) either a longer period of recruitment or expansion of recruitment sites, (ii) plans at the outset for the research team member(s) engaged in recruitment and enrollment to have specific expertise in the assessment of substance-use disorder and protocols and practices in local treatment. In addition, it may be necessary to include all patients with alcohol withdrawal risk, regardless of whether or not an addiction counselor assessed patients as having alcohol dependence, and instead relying on a research assessment to identify AUD. It is possible that research assessments would be more sensitive in identifying latent disorder in the population. Protocol completion rates among those randomized were modest at 45 days (64.8%), which approached our goal of 70%. Conducting the same level of proactive outreach with all participants even when they do not receive a study medication would likely allow us to meet this goal (approximately 77% of those who received a study medication, and thus were proactively followed, completed all follow-up interviews).
Given prior literature indicating that many inpatients with AUDs forgo follow-up treatment (Blondell et al., 2011; Saitz et al., 2007) , we were surprised that the vast majority of veterans in both study groups saw an addiction treatment specialist in the last 14 days after hospital discharge. In light of these findings, and because inpatients in need of alcohol detoxification are likely to have extensive treatment needs, our findings indicate that the most optimal measure of follow-up care would be a measure based on continued (McKay, 2005; McLellan et al., 2000) and is known to improve addiction-related outcomes (Blodgett et al., 2014; McKay, 2009 ). Because the current feasibility study did not include an inactive control group, we are unable to determine the extent these treatment initiation rates could be attributed to receiving oral or injectable naltrexone. While a goal of close to 100% follow-up of inpatients within 14 days is desirable, previous trials have found relatively modest rates of addiction treatment services when patients were identified opportunistically through alcohol screening (Saitz et al., 2007) or through a need for detoxification (Blondell et al., 2011) . Several contextual factors may have contributed to the higher rates in the current study. In 2008, the Department of Veterans Affairs instituted a performance measure monitoring 14-day outpatient follow-up of inpatients with AUDs (Kussman, 2008) .
In regard to the primary outcomes of study feasibility, we were able to recruit, retain, and interview subjects, but there were also issues that could complicate this intervention and should be considered in future research and clinical practice. Our finding that many veterans with alcohol dependence were on chronic opioids was surprising and important, because (i) use of naltrexone will be limited to a smaller segment of the population and (ii) modifications to pain management plans are likely warranted in individuals with at-risk and problem drinking due to complications such as opioid overdose, serious GI events, and hepatic injury.
Of additional potential interest was the common occurrence of regular opioid pain medication use among veterans screened for participation. Chronic heavy alcohol consumption is an independent risk factor for mortality due to toxicity from acetaminophen, a commonly used over-the-counter analgesic (Schmidt et al., 2002) . Even therapeutic doses of acetaminophen have been associated with hepatic injury and mortality among those with problem drinking (Dart et al., 2010; Kuffner et al., 2007) . Also commonly used in the setting of chronic pain, nonsteroidal anti-inflammatory agents present significant risk in the setting of heavy alcohol consumption, with an AUD history conferring an odds ratio of 10.2 for severe GI events (Neutel and Appel, 2000) . Further, alcohol is involved in a significant proportion (19%) of opioid-related emergency department visits and hospitalizations (Jones et al., 2014) . Pain management considerations may require significant attention among individuals with AUD.
Consideration should be given to alternative pharmacotherapies for chronic pain and to treatments that reduce both chronic pain and alcohol consumption. Targeted psychological pain interventions have been effective in samples of chronic pain patients in treatment for use disorders and may represent an important consideration for pain management in this population (Ilgen et al., 2016) . Additionally, pharmacotherapies effective for painful conditions (e.g., gabapentin, pregabalin) may also assist in reductions in alcohol consumption (Martinotti et al., 2013; Myrick et al., 2009) .
As expected, drinking decreased in both groups overall, which is in line with prior evidence indicating naltrexone's effectiveness in reducing heavy drinking in outpatient settings (Jonas et al., 2014) . In this particular study, how much of the reduction in alcohol consumption was due to the medication or natural process of recovery after leaving the hospital is uncertain due to the lack of a control group.
With slight modifications to the current study methods as mentioned above, a future study of similar design could test the following hypotheses: (i) that hospital-administered, long-acting injectable naltrexone reduces alcohol use more than daily oral naltrexone following hospitalization, (ii) that this reduced alcohol consumption is associated with greater engagement in substance-abuse behavioral treatment, (iii) that injectable naltrexone and improved adherence to oral naltrexone are associated with improved likelihood of attending initial visits for substance-abuse behavioral treatment when compared to patients nonadherent to recommended naltrexone dosing, and (iv) that assignment to injectable naltrexone and improved adherence to oral naltrexone are associated with reduced alcohol consumption following hospital discharge when compared with nonadherent subjects receiving oral naltrexone.
Limitations
As a pilot study, the small sample size was useful to gain information about feasibility, However, as appropriate for a pilot study, we did not seek to gain sufficient statistical power to detect significant differences in outcomes between study groups (Eldridge et al., 2016) . Also, as previously mentioned, the lack of an inactive control group limits ability to attribute improvements over time to medication conditions. The homogeneity of the sample (predominantly Caucasian male veterans) limits the potential generalizability of findings.
Injectable naltrexone is currently viewed (and frequently only covered by third-party payers) as an outpatient medication. Study results, however, indicate that the medication may be feasibly delivered during a "teachable moment," such as a hospitalization for (or hospitalization complicated by) alcohol-related issues or a residential treatment stay. If future studies demonstrate the efficacy of naltrexone in hospitalized patients, policies allowing for the administration of injectable naltrexone prior to discharge from institutional settings may foster improvements not only in patient-oriented outcomes (i.e., improved treatment uptake and reduced alcohol consumption after hospital discharge), but may also drive cost savings via reductions in repeat emergency room utilization and hospitalization due to alcohol intoxication or other alcohol-related issues. Consideration of the presence of AUD and management modifications are likely significant in the care of individuals with chronic painful conditions.
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